Enanta Pharmaceuticals (NASDAQ:ENTA) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a hold rating to a sell rating in a report published on Sunday morning,Wall Street Zen reports.

Other analysts have also recently issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Wednesday, September 23rd. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $19.00.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ:ENTA opened at $11.52 on Friday. Enanta Pharmaceuticals has a 52-week low of $10.20 and a 52-week high of $17.15. The business has a 50-day moving average price of $13.04 and a 200-day moving average price of $13.27.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%. The firm had revenue of $14.36 million for the quarter, compared to analyst estimates of $16.76 million. Analysts forecast that Enanta Pharmaceuticals will post -2.36 EPS for the current year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several hedge funds have recently modified their holdings of ENTA. Jupiter Topco LLC purchased a new stake in shares of Enanta Pharmaceuticals in the second quarter valued at approximately $53,252,000. BlackRock Inc. purchased a new position in shares of Enanta Pharmaceuticals during the 2nd quarter valued at approximately $47,304,000. ADAR1 Capital Management LLC purchased a new position in shares of Enanta Pharmaceuticals during the 2nd quarter valued at approximately $19,603,000. Spruce Street Capital LP purchased a new position in shares of Enanta Pharmaceuticals during the 2nd quarter valued at approximately $15,873,698. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Enanta Pharmaceuticals in the 2nd quarter valued at $2,231,000. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and liver diseases. The company’s research and development activities have included treatments for hepatitis B virus (HBV), respiratory syncytial virus (RSV), SARS-CoV-2 and other infectious diseases.

Enanta’s most notable commercial contribution is glecaprevir, a direct-acting antiviral developed in collaboration with AbbVie and included in the Mavyret and Maviret treatment for chronic hepatitis C virus (HCV) infection.